ArticleFrontiers in pharmacology2021

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer.

Xiaomin Wan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.